glp 1 chronic kidney disease Frontiers Antiinflammatory actions of GLP-1 medicines

Cells were treated with various concentrations of URB597 or 4-(3-chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide (BCTC) (0.02, 0.5, 2 mol/L, Cayman Chemical Company, Ann Arbor, MI, USA), SR144528 (0.02, 0.5, 2 mol/L, EMD Millipore, Etobicoke, ON, Canada), indomethacin (2, 20, 50 mol/L, Sigma-Aldrich, Oakville, ON, Canada), or vehicle solution (0.1% dimethyl sulfoxide, DMSO) and incubated for 15 min at 37 C in 5% CO 2

Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease Aoi, W., et al

Neuropata ptica isqumica anterior no artertica (NAION) Un estudio de cohorte con poblacin de referencia neuro-oftalmolgica (y pacientes con diabetes) muestra un mayor riesgo de NAION con semaglutida vs otros frmacos en diabetes ( HR 4,28 ) y en sobrepeso/obesidad ( HR 7,64 ) (28)

Turmeric black pepper extract

Microvessel density: integrating sex-based differences and elevated cardiovascular risks in metabolic syndrome